Late-breaking Trials II
In this PVI Course 2024 session dedicated to LBTs, experts share recent findings on lower extremity treatments. The 12-month results from the ELEGANCE Registry highlight more advanced clinical presentations in females and black patients, yet revascularisation shows low amputation and re-intervention rates across diverse groups. The PRIZER study reveals improvements in clinical assessment and ABI for femoral-popliteal treatments, with room for better training and data delivery. The ELLIPSE study shows that combining atherectomy and balloon treatment for complex lesions is safe and effective. Insights from the French Nationwide Claims Database suggest lower mortality and amputation rates with specific endoprostheses compared to open surgery. Lastly, the REALDES study presents 3-year results, showing significant differences in restenosis and re-occlusion rates.
Professor of Vascular Surgery
President of the association of the french university hospitals for clinical research
Conflicts of interest:
Research funding from Predisurge, Biotronik, WL Gore, GE Healthcare
Honoraria from Abbott, BD, Bentely, Biotronik, Boston Scientific, Cook, Eclevar Medtech, GE Healthcare, Ivascular, Medtronic, Penumbra, Sensome, Shockwave medical, WL Gore (consulting, medical advisory board, educational course, speaking)
